Teva Pharmaceutical Completes Agreement to Acquire Emalex Biosciences

Faegre Drinker advised leading biopharmaceutical company Teva Pharmaceutical in its agreement to acquire Emalex Biosciences, expanding Teva's innovative medicines pipeline and supporting their growth. 

Emalex Biosciences was created to develop new treatments for central nervous system disorders and other conditions with limited treatment options. Emalex's lead asset, ecopipam, is a first-in-class investigational asset for pediatric Tourette syndrome with FDA Orphan Drug and Fast Track designations. 

Upon closing, Teva will pay $700 million, and Emalex's shareholders will be eligible to receive up to $200 million based on future commercial milestones as well as royalties on global net sales of ecopipam, subject to regulatory approval. The transaction is subject to customary closing conditions, including receipt of necessary regulatory approvals.